Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Bundred, Nigel; Campbell, Ian; Davidson, Neville; DeBoer, R.; Eidtmann, Holger; Monnier, Alain; Neven, Patrick; von Minckwitz, Gϋnter; Miller, J.; Schenk, Nora; E. Coleman, Robert

doi:10.1002/cncr.23259

Public

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Published in Cancer • Jan 18, 2008

Authors:

Nigel Bundred

Ian Campbell

Neville Davidson

Abstract

BACKGROUND: Letrozole is safe and effective in postmenopausal women with estrogen receptor-positive early breast cancer, but long-term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection therapy with zoledro...

Subject

Medicine

Zoledronic acid

Letrozole

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!